annb0t
Top 20
MELBOURNE, Australia, April 12, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its ProstACT TARGET Phase II clinical trial of the Company's prostate cancer antibody therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients experiencing a first recurrence of prostate-specific antigen (PSA) after initial therapy for prostate cancer, has been granted Human Research Ethics Committee (HREC) approval.
Telix's primary goal with the ProstACT study...
>>> Read more: ProstACT Update: TARGET Study Ethics Approval
Telix's primary goal with the ProstACT study...
>>> Read more: ProstACT Update: TARGET Study Ethics Approval
